Comparative Pharmacology
Head-to-head clinical analysis: MYKACET versus PERCOCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYKACET versus PERCOCET.
MYKACET vs PERCOCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MYKACET (acetaminophen) is a centrally acting analgesic and antipyretic. Its exact mechanism is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) isoenzymes in the central nervous system, particularly COX-2, and modulation of descending serotonergic pathways.
Oxycodone is a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception and emotional response. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis and exerting analgesic and antipyretic effects.
4 g intravenous every 8 hours over 3 hours, based on piperacillin 4 g and tazobactam 0.5 g.
One tablet (5 mg oxycodone/325 mg acetaminophen) every 6 hours as needed for pain; maximum 12 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; extended to 12-24 hours in moderate to severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Oxycodone: 3.5–4.5 hours (terminal) in normal renal function; prolonged in hepatic/renal impairment (up to 6–12 hours). Acetaminophen: 2–3 hours (terminal) in overdose, extended with hepatic injury.
Primarily renal excretion of unchanged drug via glomerular filtration and active tubular secretion; >90% of administered dose appears in urine within 24 hours; minimal biliary/fecal elimination (<5%).
Oxycodone: primarily renal (up to 19% as unchanged drug, 50% as noroxycodone and oxymorphone metabolites); about 10% biliary/fecal. Acetaminophen: renal (majority as glucuronide and sulfate conjugates, about 5% unchanged).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination